



D2 Announcement

As previously announced, D2 Pharma Consulting LLC has been selected by Theravance Biopharma to provide managed markets support for VIBATIV® (telavancin). In addition, we are very excited to bring you more news regarding the ongoing availability of VIBATIV.

Effective January 1, 2017, Theravance Biopharma will be participating in the Centers for Medicare & Medicaid Services (CMS) Coverage Gap Discount Program. This means VIBATIV will now be eligible for Part D coverage under the following CMS approved labeler codes:

- 52118 Theravance
- 62847 Theravance Biopharma Antibiotics, Inc.

VIBATIV coverage has previously been available under Medicare Part A and B, and now has expanded Part D eligibility coverage.

VIBATIV is the only FDA approved once-daily bactericidal antibiotic indicated for the treatment of the following infections in adult patients caused by designated susceptible bacteria:

- Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Staphylococcus aureus. In HABP/VABP, VIBATIV should be reserved for use when alternative treatments are not suitable.
- Complicated skin and skin structure infections (cSSSI).

Product Formulation	750 mg IV (vials)
VIBATIV NDC #	52118-0001-01 62847-001-01

We look forward to addressing any VIBATIV Part D coverage questions and providing you with VIBATIV clinical information upon request. Thank you for your continued support.

Full Prescribing Information, including Boxed Warning and Medication Guide, is available at www.VIBATIV.com.

Respectfully,

Dean P. Erhardt
President
D2 Consulting

Respectfully,

Director of Managed Markets and Reimbursement
Theravance, Biopharma